ReviewCellular & molecular biology letters2026
G-quadruplex stabilization via small molecules as a potential anti-cancer strategy.
Review in Cellular & molecular biology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mechanistic and structural elucidation of π-π end-stacking interactions of a novel SORSC advances · 2026Article
- Dibenzoacridinium derivatives: a new class of G-quadruplex ligands with anti-HIV-1 properties.RSC medicinal chemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
G-quadruplexes (G4s) are noncanonical nucleic acid secondary structures formed by guanine-rich DNA or RNA sequences, predominantly located at telomeric ends and within the promoter regions of oncogenes. These structures play essential roles in maintaining telomere stability, regulating DNA replication, and modulating gene transcription and translation. Stabilization of G4 structures can induce cellular senescence and apoptosis while suppressing oncogene expression, positioning them as highly promising therapeutic targets in anticancer research. In recent years, a variety of small-molecule G4 ligands have been developed, many of which exhibit potent antitumor activity by selectively stabilizing G4s. Targeting G4s has thus emerged as a cutting-edge strategy in cancer therapy, offering new avenues for precision medicine. This review provides a comprehensive overview of G4 structure and function, highlights recent progress in the development of G4-targeting ligands, and discusses their therapeutic potential in oncology. Our goal is to offer insights into the design and application of G4-targeted agents for future anticancer drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.